# US 2022/0031695 A1 · Shp2 inhibitor compositions for use in treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031695 A1
- Document ID: US20220031695A1
- Status: Published application
- Kind: A1
- Application number: 17/224,025
- Filed: 2021-04-06
- Published: 2022-02-03
- Earliest claimed: 2018-10-08
- Assignees: Revolution Medicines, Inc.
- Applicants: Revolution Medicines, Inc.; The Regents of the University of California
- Inventors: Robert J. NICHOLS; Trever G. BIVONA; Dana NEEL
- Web page: https://patentgrep.com/patent/US20220031695A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/47: Quinolines; Isoquinolines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- G01N 33/575: for cancer
- G01N 33/57575: {involving oncogenic proteins}
- G01N 2333/9121: with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/7028: Cancer
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides methods of treating diseases or disorders using allosteric inhibitors of SHP2 and to methods and diagnostic tests for identifying subjects likely to respond to such allosteric inhibitors of SHP2. In particular, the present disclosure provides diagnostic and therapeutic uses related to certain Receptor Tyrosine Kinase (RTK) mutations that are indicative of sensitivity to allosteric SHP2 inhibitors.

## Claims

### Claim 1

A method for identifying whether a subject has a cancer that is sensitive to SHP2 inhibition, the method comprising determining whether the cancer comprises one or more cells containing an oncogenic tyrosine kinase fusion that causes MAPK activation, and, if so, identifying the subject as having a cancer that is sensitive to SHP2 inhibition.

### Claim 2

(canceled)

### Claim 3

A method for killing cancer cells with a SHP2 inhibitor, the method comprising the steps of:
a. determining whether the cancer cells contain an oncogenic tyrosine kinase fusion that causes MAPK activation; and
b. contacting the cancer cells with the SHP2 inhibitor if the cancer cells contain an oncogenic tyrosine kinase fusion that causes MAPK activation.

### Claim 4

A method for treating a patient with a SHP2 inhibitor, wherein the patient has cancer, the method comprising the steps of:
a. determining whether the patient has a SHP2-sensitive cancer by:
i. obtaining or having obtained a biological sample from the patient; and
ii. performing or having performed an assay on the biological sample to determine if the patient has a tumor comprising one or more cells that contain an oncogenic tyrosine kinase fusion that causes MAPK activation; and
b. administering the SHP2 inhibitor to the patient if the patient has a tumor comprising one or more cells containing an oncogenic tyrosine kinase fusion that causes MAPK activation.

### Claim 5 (depends on 4)

The method of claim 4, wherein the SHP2 inhibitor is selected from (i) NSC-87877; (ii) TN0155, (iii) of any one of Formula I, of Formula II, of Formula III, of Formula I-V1, of Formula I-V2, of Formula I-W, of Formula I-X, of Formula I-Y, of Formula I-Z, of Formula IV, of Formula V, of Formula VI, of Formula IV-X, of Formula IV-Y, of Formula IV-Z, of Formula VII, of Formula VIII, of Formula IX, and of Formula X disclosed herein; (iv) Compound C; (v) a SHP2 inhibitor listed on Table 1; (vi) a SHP2 inhibitor listed on Table 2; (vii) a pharmaceutically acceptable salt prodrug, solvate, hydrate, tautomer, or stereoisomer of any one of (i)-(vi), and (vii) combinations thereof.

### Claim 6

(canceled)

### Claim 7 (depends on 4)

The method of claim 4, wherein the oncogenic tyrosine kinase fusion is selected from a ROS1 fusions, an ALK fusion, a RET fusion, an NTRK1 fusion, an NTRK2 fusion, and an NTRK3 fusion.

### Claim 8 (depends on 4)

The method of claim 4, wherein the oncogenic tyrosine kinase fusion is a SDC4-ROS1 fusion or an SLC34A2-ROS1 fusion.

### Claim 9 (depends on 4)

The method of claim 4, wherein the oncogenic tyrosine kinase fusion is selected from a FIG-ROS1 fusion; a LRIG3-ROS1 fusion; an EZR-ROS1 fusion, and a TPM3-ROS1 fusion.

### Claim 10 (depends on 4)

The method of claim 4, wherein the oncogenic tyrosine kinase fusion is selected from an EML4-ALK fusion.

### Claim 11 (depends on 4)

The method of claim 4, wherein the MAPK activation is detected by measuring increased ERK phosphorylation.

### Claim 12 (depends on 4)

The method of claim 4, wherein determining whether the cancer cells contain an oncogenic tyrosine kinase fusion that causes MAPK activation is achieved by genotyping a cell or cells in a biological sample obtained from the patient.

### Claim 13 (depends on 12)

The method of claim 12, wherein the genotyping determines whether the cancer comprises a cell containing an oncogenic tyrosine kinase fusion selected from EML4-ALK, SDC4-ROS1 and SLC34A2-ROS1.

### Claim 14 (depends on 4)

The method of claim 4, wherein if the cancer does not comprise any cells containing an oncogenic tyrosine kinase fusion that causes MAPK activation, then the method comprises administering a cancer therapy selected from chemotherapy, radiation therapy, and/or surgical tumor resection.

### Claim 15

A method for treating a subject having a tumor with a SHP2 inhibitor, the method comprising:
a. determining whether a biological sample obtained from the subject contains an oncogenic tyrosine kinase fusion protein comprising a N-terminal fusion partner that causes the fusion protein to localize in an endosome; and
b. administering to the subject an inhibitor of SHP2 if the biological sample contains an oncogenic tyrosine kinase fusion protein comprising a N-terminal fusion partner that causes the fusion protein to localize in an endosome.

### Claim 16 (depends on 15)

The method of claim 15, wherein the oncogenic tyrosine kinase fusion protein causes MAPK activation.

### Claim 17 (depends on 15)

The method of claim 15, wherein the method further comprises administering a cancer therapy selected from chemotherapy, radiation therapy, and/or surgical tumor resection.

### Claim 18 (depends on 15)

The method of claim 15, wherein the method further comprises administering an additional therapeutic agent.

### Claim 19 (depends on 3)

The method of claim 3, wherein the contacting occurs in vivo in a subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the contacting occurs via administration of the SHP2 inhibitor to the subject.

### Claim 21 (depends on 20)

The method of claim 20, wherein the method further comprises administering a cancer therapy selected from chemotherapy, radiation therapy, and/or surgical tumor resection.

### Claim 22 (depends on 20)

The method of claim 20, wherein the method further comprises administering an additional therapeutic agent.

### Claim 23 (depends on 18)

The method of claim 18, wherein the additional therapeutic agent is selected from a TKI, a MAPK pathway inhibitor, an EGFR inhibitor, an ALK inhibitor, and a MEK inhibitor.

### Claim 24 (depends on 18)

The method of claim 18, wherein the additional therapeutic agent is (i) a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or stereoisomer of a TKI, a MAPK pathway inhibitor, an EGFR inhibitor, an ALK inhibitor, or a MEK inhibitor, or (ii) a combination of any two or more of such pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or stereoisomers recited in (i).

### Claim at position 25

25-28. (canceled)

### Claim 29 (depends on 1, 3, 4, 15)

The method of any one of claims 1, 3, 4 or 15, wherein the SHP2 inhibitor is
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or stereoisomer thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the SHP2 inhibitor is
